Top Markets
Coin of the day
Cardiol Therapeutics Inc. Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc.

CRDL
Classifica tra le azioni #17188
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company,... Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
Prezzo delle azioni
$2.17
Capitalizzazione di mercato
$249.58M
Variazione (1 giorno)
-1.67%
Variazione (1 anno)
96.34%
Paese
CA
Scambia Cardiol Therapeutics Inc. (CRDL)

Categoria

Utile per Cardiol Therapeutics Inc. (CRDL)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Cardiol Therapeutics Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Cardiol Therapeutics Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti